NEW YORK, NY -- (Marketwire) -- 11/27/12 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) is focused on the acute treatment of central nervous system conditions. Alexa's lead program, ADASUVE, New Drug Application has a PDUFA goal date of December 21, 2012.

Find out more about Alexza Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ALXA

ANADIGICS, Inc. (NASDAQ: ANAD) shares of the semiconductor company surged over 20 percent on nearly 5 times the average daily volume Monday. Analysts at Needham have upgraded the company's rating to "buy" from "hold" and gave a price target of $2.50.

Find out more about ANADIGICS including full access to the free equity report at: www.BedfordReport.com/ANAD

Galectin Therapeutics Inc. (NASDAQ: GALT) is focused on the development of new therapies for fibrotic disease and cancer. Shares of the company surged nearly 20 percent Monday after reporting it has received a U.S. patent for a second drug class to treat chronic liver disease with fibrosis and cirrhosis.

Find out more about Galectin Therapeutics including full access to the free equity report at: www.BedfordReport.com/GALT

Mcmoran Exploration Co. (NYSE: MMR) shares of the oil & gas company fell 22.5 percent on nearly 20 million shares traded Monday after providing an update on their Gulf of Mexico exploration and development activities.

Find out more about Mcmoran Exploration including full access to the free equity report at: www.BedfordReport.com/MMR

Disclaimer: Equity News Circuit is not a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security. A third party, bedfordreport.com has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release.